RBC Capital Initiates Coverage On Krystal Biotech with Outperform Rating, Announces Price Target of $400
Krystal Biotech, Inc.
Krystal Biotech, Inc. KRYS | 0.00 |
RBC Capital analyst Lisa Walter initiates coverage on Krystal Biotech (NASDAQ:
KRYS) with a Outperform rating and announces Price Target of $400.